aTYR PHARMA (ATYR) Share-based Compensation (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Share-based Compensation came in at $1.3 million in Q1 2026, up 10.95% YoY from $1.2 million in Q1 2025, and up 8.29% on a QoQ basis from $1.2 million in Q4 2025.
aTYR PHARMA (ATYR) Share-based Compensation (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Share-based Compensation data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 10.95% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 1070.32% YoY) and the FY2025 annual result came in at $5.0 million, changed N/A from the prior year.
- Share-based Compensation climbed to $1.3 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q4 2022 to a low of -$2.2 million in Q4 2024.
- A 5-year average of $736312.5 and a median of $746000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 227.05% — and 2024, when it slumped 454.47%.
- Tracing ATYR's Share-based Compensation over 5 years: stood at $1.4 million in 2022, then tumbled by 53.77% to $626000.0 in 2023, then tumbled by 454.47% to -$2.2 million in 2024, then surged by 154.39% to $1.2 million in 2025, then rose by 8.29% to $1.3 million in 2026.
- The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 1.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.15 Mn |
| Jun 30, 2026 | 1.15 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | -2.22 Mn |
| Dec 31, 2024 | -2.22 Mn |
| Sep 30, 2024 | 752,000.00 |
| Sep 30, 2024 | 752,000.00 |
| Jun 30, 2024 | 727,000.00 |
| Jun 30, 2024 | 727,000.00 |
| Mar 31, 2024 | 740,000.00 |
| Mar 31, 2024 | 740,000.00 |